1120 results about "Albumin" patented technology

Provided herein are albumin binding proteins and methods of making and using thereof.

The invention belongs to the cross technical field of nanomedicine, tumor treatment and immunotherapy, and particularly provides tumor mitochondria-targeted copper death selective induction nanoparticles, which are prepared by the following preparation method: S1, specifically coupling TPY and MHI through condensation reaction to obtain MTPY; s2, MTPY and copper ions are subjected to complexation, and an MTPY-Cu complex is obtained; and S3, the MTPY-Cu complex and albumin are subjected to self-assembly, and the MTPY-Cu-coated Alb nanoparticles are formed. The dosage of copper is only 1 / 1000 of that of free Cu < 2 + >, and equivalent immune regulation and killing effects can be achieved; primary tumors and distant tumor focuses can be inhibited, and lung metastasis is reduced; immune memory can be induced, and relapse can be prevented; the traditional Chinese medicine composition is combined with cis-platinum to remarkably enhance the curative effect and reverse the induced immunosuppression; the invention has the advantages of high biological safety and no obvious liver and kidney toxicity or hemolytic reaction.

Provided herein are albumin binding proteins and methods of making and using thereof.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

Provided herein are albumin binding proteins and methods of making and using thereof.

The invention belongs to the technical field of biological detection, and discloses a kit and a method for quantitatively detecting residual quantity of host cell protein of pichia pastoris in order to solve the problems of limit of quantitation and low detection sensitivity of an existing detection method. According to the present invention, the empty plasmid without the recombinant human serum albumin gene is introduced into the pichia pastoris, and purification is performed by combining the Protein A chromatographic column and the host cell protein coupling affinity column, such that the prepared polyclonal antibody can be effectively used for the quantitative detection of the residual amount of the pichia pastoris host cell protein in the biological product; the kit formed by the polyclonal antibody has good accuracy and repeatability on the quantitative detection of the host cell protein residues in the pichia pastoris source biological products, the quantification limit is 0.2 ng / mL, and the kit provided by the invention can meet the quantitative detection of the host cell protein residues in all the pichia pastoris source biological products.

The invention discloses a nutritional composition for promoting neurodevelopment and application, and provides a nutritional composition for promoting neurodevelopment, which comprises the following necessary components: a sialylated substance component comprising one or more of N-acetylneuraminic acid, sialylated oligosaccharide, sialylated protein and sialylated lipid; the whey protein component comprises alpha-lactalbumin; and a peptide component from casein, including a hydrolysate of casein; the nutritional composition comprises a sialylated substance component, a whey protein component and a casein-derived peptide component, and the mass ratio of the sialylated substance component, the whey protein component and the casein-derived peptide component in the nutritional composition is (0.5-10): (300-1): (100-0.5). The nutritional composition provided by the invention can promote brain development and cognitive functions, and can significantly promote neurodevelopment by scientifically matching the sialylated substance component, the whey protein component and the peptide component from casein.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The invention provides a composite quality control liquid for an electrochemical multi-parameter detector. The composite quality control liquid comprises a buffer volume, a quality control substance and a stabilizer, the stabilizing agent comprises 5 to 50 g / L of bovine serum albumin, 0.1 to 10 g / L of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 10 to 100 g / L of a viscosity regulator, 0.3 to 25 g / L of a preservative and 5 to 20 g / L of a surfactant; the preparation method comprises the following steps: adding components of the stabilizer into a buffer system, preparing a preparation solution, preparing mother liquor of each quality control substance, proportionally mixing glucose mother liquor, uric acid mother liquor, beta-hydroxybutyric acid mother liquor and cholesterol sodium sulfate and triglyceride composite mother liquor according to the target concentration of the quality control solution, and fixing the volume by using the preparation solution to obtain the quality control liquid. And fully and uniformly mixing to obtain the composite quality control liquid. The composite quality control liquid can ensure that uric acid is not degraded, cholesterol triglyceride is not separated out, the formula is mild, and active substances in a detection system are not influenced.

The invention discloses a composite microecological preparation as well as a preparation method and application thereof. The compound microecological preparation disclosed by the invention comprises lactobacillus casei, lactobacillus plantarum and saccharomyces cerevisiae. The application effect of the composite microecological preparation in cow breeding is remarkable, the optimal addition amount of the composite microecological preparation is 100 mL / cow / day, the production performance of lactating cows can be improved, the milk yield is improved by 3.30 kg / cow / day, the milk yield of 4% standard milk is improved by 3.78 kg / cow / day, the total protein is improved by 15.9%, the albumin is improved by 14.7%, the globulin is improved by 16.5%, and the somatic cell number is reduced by 52.6%; and pollutant emission can be reduced, including 37.2% of ammonia emission reduction and 28.7% of carbon dioxide emission reduction.

The invention relates to a double-framework self-developing embolism system based on iodine modified PNIPAM gel and cross-linked albumin microspheres, which simulates a brick wall-concrete effect through a microsphere-gel composite structure and synergistically improves the embolism strength. A novel TACE treatment system is designed and constructed, multiple effects of tracing, embolism, hypoxia enhanced chemotherapy and tumor microenvironment improvement are achieved through the self-developing temperature-sensitive gel-drug carrying microspheres, and the anti-tumor effect is cooperatively improved.

The present disclosure provides, among other things, single domain antibodies that bind to human serum albumin. Pharmaceutical compositions comprising the single domain antibodies disclosed herein are provided.

This invention relates to the field of chicken gizzard lining processing technology, and particularly to an active polypeptide of chicken gizzard lining, its preparation method, and functional products. The preparation method includes the following steps: mixing chicken gizzard lining powder with water and subjecting it to alkaline heat treatment to form a slurry; sequentially adding Bacillus licheniformis alkaline protease, trypsin, and pepsin to the slurry for three separate hydrolysis processes to obtain a hydrolysate; after enzyme inactivation treatment of the hydrolysate, adding Lactobacillus plantarum for fermentation to obtain a fermentation broth; sterilizing the fermentation broth and then filtering it to obtain a fermentation supernatant; sequentially subjecting the fermentation supernatant to membrane filtration, sterilization, and spray drying to obtain the active polypeptide of chicken gizzard lining. The active polypeptide of chicken gizzard lining prepared by the method of this invention exhibits alcohol dehydrogenase activating activity, AGEs inhibitory activity, albumin denaturation inhibitory activity, lipoxygenase inhibitory activity, pancreatic lipase inhibitory activity, and a beneficial bacteria proliferation promoting effect.

The invention relates to hyaluronic acid-based nanogel with intestinal targeting and inflammation responsiveness as well as a preparation method and application of the hyaluronic acid-based nanogel, and discloses multifunctional composite nanogel based on hyaluronic acid as well as a preparation method and application of the multifunctional composite nanogel. The preparation method comprises the following steps: loading galangin into bovine serum albumin to prepare BSA-GA nanoparticles with antioxidant and anti-inflammatory activity; 2, synthesizing a multifunctional molecule Se-MHA which is targeted to M2 macrophages and responds to ROS degradation on the basis of hyaluronic acid; 3, BSA-GA nano-particles with the same solution concentration are used as anti-inflammatory functional components to be mixed with Se-MHA to prepare Se-MHA / BG nano-gel, model probiotics are subjected to single-cell modification, probiotic-loaded nano-gel EcN-Se-MHA / BG is prepared, the nano-gel has specific binding and responding capacity on the colitis disease part, colonization of EcN on the colon part is promoted, and the anti-inflammatory effect is achieved. The IBD disease is effectively relieved.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.

A pharmaceutical composition comprises a GPCR agonist fusion protein wherein the GPCR agonist peptide is covalently conjugated to an albumin via a linker in a manner that is resistant to a reverse Michael addition. Advantageously, the compositions presented herein avoid uncoupling of the agonist to the albumin while maintaining the agonist and the albumin in a spatial relationship that allows efficient binding and activation of the GPCR while also enabling gp60-mediated endocytosis transport and FcRn-mediated albumin recirculation. These characteristics enable ultra-low doses of GPCR agonist fusion proteins to produce therapeutic effects while significantly reducing or even completely avoiding side effects that would otherwise be typically associated with unbound agonists. Such reverse Michael resistant compositions are typically achieved by conformationally modifying an albumin, resulting in a stereoselective coupling of a linker to the albumin.

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

The invention relates to absorbable adhesive styptic powder and a preparation method thereof, and the absorbable adhesive styptic powder is characterized in that the absorbable adhesive styptic powder is formed by cross-linking aldehyde polysaccharide and a polyamino compound through Schiff base reaction, the raw materials are selected from at least one of glucan, sodium carboxymethyl cellulose, sodium hyaluronate, chitosan and carboxymethyl starch; the polyamino compound is selected from at least one of polylysine, polypeptide, bovine serum albumin and polyamine; the styptic powder is porous particles with the particle size of 10-1000 meshes, is cured into gel within 10 seconds after being in contact with body fluid, and is completely degraded within 15-60 days. According to the scheme, the styptic powder has the advantages of rapid wet adhesion, controllable degradation and excellent processability, and is an urgent clinical demand.

The invention discloses a special ultralow-temperature preservative for blood T cells and application of the special ultralow-temperature preservative, and the special ultralow-temperature preservative comprises the following components in percentage by mass and volume: an osmotic pressure regulating system (5-10% of glycerol and 10-20% of glycolalcohol which are compounded); an antioxidant protection system (10%-20% of human serum albumin and 0.1%-1% of glutathione); a nutrition supply agent (a cell culture medium containing glucose, amino acid, vitamin and electrolyte); a pH stable buffer pair (0.5%-3% of HEPES and 0.1%-1% of sodium bicarbonate); and a cell membrane enhancer (1%-1% of cholesterol and 0.05%-0.5% of phosphatidylcholine). The pH value of the preservative is 7.2-7.4, the preservative is suitable for long-time cryopreservation of blood T cells at the ultralow temperature of-80 DEG C to-196 DEG C, and the biological activity and functional integrity of the T cells can be effectively maintained. The invention also relates to an application of the preservative in preparation of T cell preparations preserved at ultra-low temperature, and the survival rate and functional integrity of cells after cryopreservation can be obviously improved.

The invention provides an immobilized carrier based on bovine serum albumin-biotin as well as a preparation method and application of the immobilized carrier. The biological sample fixing carrier comprises a substrate and a composite layer of bovine serum albumin coupled biotin and neutral avidin, wherein the composite layer is fixed on the surface of the substrate; the bovine serum albumin coupled biotin and neutral avidin composite layer is connected to the surface of the substrate after being co-incubated with the substrate through bovine serum albumin coupled biotin, and then the neutral avidin is combined with biotin in the bovine serum albumin coupled biotin through co-incubation with the neutral avidin; the bovine serum albumin coupled biotin and neutral avidin composite layer is fixed on the surface of the substrate. The biomolecules on the surface of the carrier are high in fixing efficiency, good in uniformity, high in adaptability, high in signal-to-noise ratio and easy to operate.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention provides a postoperative bleeding risk monitoring method and system for a hepatobiliary patient. The method comprises the following steps: collecting real-time multi-modal data; constructing an LSTM-CNN hybrid model by using the time-frequency decomposition features, and obtaining a local tissue hypoxia index and a vasomotor function anomaly probability; the low-frequency impedance change rate and the albumin level are fused through a random forest algorithm, and the ascites occurrence probability and the effusion amount predicted value are obtained; and generating a bleeding point positioning coordinate and a thermodynamic diagram risk grade. And calculating a comprehensive bleeding risk probability and positioning a bleeding area. And generating graded early warning signals and recommending personalized treatment schemes or nursing suggestions. According to the invention, the LSTM-CNN hybrid model, the random forest algorithm and the three-dimensional convolutional neural network are adopted to deeply extract different data features, so that the limitation of single index evaluation is avoided. A causal relationship model is established through the Bayesian network, and the comprehensive risk probability calculation preciseness is improved; the early warning threshold is dynamically adjusted by combining the individual characteristics of the patient, and the traditional problem of easy misjudgment is solved.

The invention relates to the technical field of biological and medical diagnosis, in particular to a biomarker for predicting whether a patient suffering from pyotoxic myocardial injury has a short-term death risk or not and application of the biomarker, and the biomarker is the ratio of erythrocyte distribution width to albumin. According to the method, retrospective queue research design is adopted, two data sets, namely MIMIC-IV and eICU-CRD, are used, suppurative myocardial injury patients meeting conditions are included, covariants such as baseline features, laboratory inspection results and complication information of the patients are collected, the patients are divided into two groups according to RAR medians, the relation between RAR and short-term death of the patients is analyzed by adopting multiple statistical methods, and the accuracy of the short-term death of the patients is improved. A risk prediction model of short-term death of the patient suffering from the pyotoxic myocardial injury is constructed, so that a clinician can identify the patient suffering from the pyotoxic myocardial injury with high death risk in an early stage, a personalized treatment strategy can be formulated more accurately, the survival rate of the patient suffering from the pyotoxic myocardial injury is increased, and the method has a wide application prospect.

The invention provides a synthesis method of adsorption resin for removing immune globulin, and relates to a high polymer material synthesis technology, polyethylene glycol (PEG) or sulfobetaine (SBMA) is grafted through RAFT polymerization, the thickness of a grafting layer is 50-150nm, the nonspecific adsorption capacity of albumin is less than 5ng / cm < 2 >, photosensitive groups (such as phenyl azide) and ultraviolet light (254nm) are introduced to trigger crosslinking, and the coating shedding rate is less than 0.5% / time. According to the present invention, the cyclic stability is improved by 2 times, the Protein A directional capture antibody is grafted on the surface of the acrylic resin grafted with the polyethylene glycol or sulfobetaine, the IgG adsorption capacity achieves 150 mg / g, the specificity is more than 95%, the polyethylene glycol (PEG) is grafted on the surface of the magnetic particle by using ATRP / RAFT controllable polymerization, the organic solvent use amount is reduced by more than 80%, and the product adsorption capacity achieves 150 mg / g.

1. The name of the design product: packaging box (Baiyisheng Liao-Shen composite albumin peptide). 2. The use of the design product: used for the outer packaging box of articles. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view 1.

The present application provides antigen-binding proteins (e.g., antibodies such as single- domain antibodies) that specifically bind to serum albumin. The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins and uses thereof.

The invention relates to the technical field of medicine preparation, and provides a bortezomib nano composition, and the bortezomib nano composition comprises the following components: bortezomib, albumin and a medium. The bortezomib nano composition can be delivered in a targeted manner, is low in toxicity and stable, and provides a new strategy for treatment of multiple myeloma.

The invention discloses a traditional Chinese medicine compound for reducing urine protein, a traditional Chinese medicine preparation and a preparation method thereof, belongs to the technical field of traditional Chinese medicine compounds, and solves the problems that although the existing western medicine can reduce the urine protein level of a patient to a certain extent, the adverse reaction risk is high; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of prepared rehmannia root, 10-30 parts of Chinese yam, 10-30 parts of dogwood, 10-20 parts of achyranthes root, 5-15 parts of schisandra chinensis, 5-15 parts of semen cuscutae, 10-30 parts of corn stigma, 10-30 parts of rhizoma alismatis, 10-30 parts of astragalus membranaceus, 10-30 parts of fried fructus rosae laevigatae, 10-30 parts of gordon euryale seed, 5-15 parts of flatstem milkvetch seed, 5-30 parts of salvia miltiorrhiza, 3-10 parts of wine-treated rhubarb and 3-5 parts of wine-treated coptis chinensis. According to the traditional Chinese medicine composition, all the medicines are compatible, all the components complement each other, the effects of reducing urinary albumin and protecting the kidney are increased, all the components are reasonably compatible, and the effect of coordinating and synergism is achieved.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.